ADC Therapeutics Unveils Strategic Financial Restructuring to Strengthen Capital Structure
ADCT sits 71% above its 52-week low of $0.78.
Summary
ADC Therapeutics announced a comprehensive strategic financial restructuring aimed at improving its capital structure, including an $86.6 million private placement that extends its expected cash runway into 2029. The move follows FDA concerns about the LOTIS-5 trial and a Q2 loss that beat consensus. The restructuring likely addresses liquidity and debt obligations, which is critical for a company with a market cap near $181 million.
At the time of this announcement, ADCT was trading at $1.33 on NYSE in the Life Sciences sector, with a market capitalization of approximately $181.3M. The 52-week trading range was $0.78 to $4.98. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.